Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer

Authors

Jacqueline V Aredo, University of California, San Francisco
Heather A Wakelee, Stanford University
Angela Bik-Yu Hui, Stanford University
Sukhmani K Padda, Cedars-Sinai Medical Center
Nitin D Joshi, Stanford Healthcare
H Henry Guo, Stanford University
Aadel Chaudhuri, Washington University School of Medicine in St. Louis
Maximilian Diehn, Stanford University
Billy W Loo Jr, Stanford University
Joel W Neal, Stanford University

Journal

Cancer Treatment and Research Communications

Publication Date

1-1-2022

Volume

33

First Page

100659

Document Type

Open Access Publication

DOI

10.1016/j.ctarc.2022.100659

Rights and Permissions

Aredo JV, Wakelee HA, Hui AB, Padda SK, Joshi ND, Guo HH, Chaudhuri A, Diehn M, Loo BW Jr, Neal JW. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treat Res Commun. 2022;33:100659. doi: 10.1016/j.ctarc.2022.100659. © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Aredo, Jacqueline V; Wakelee, Heather A; Hui, Angela Bik-Yu; Padda, Sukhmani K; Joshi, Nitin D; Guo, H Henry; Chaudhuri, Aadel; Diehn, Maximilian; Loo, Billy W Jr; and Neal, Joel W, "Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer." Cancer Treatment and Research Communications. 33, 100659 (2022).
https://digitalcommons.wustl.edu/oa_4/1241